Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 15.05 · gapped above the open, then crossed back over prior close. High/low 16.16 at 4:15 am ET, 14.81 at 11:15 am ET.
Trevi Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Trevi Therapeutics, Inc. has 4 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Trevi Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“• our potential obligation to make milestone payments to Keenova Therapeutics plc, or Keenova, which would become due upon the successful completion of the first Phase 3 clinical trial of a licensed product candidate and the marketing approval of a licensed product in the U.S., as well as our potential obligations to pay Keenova royalties on the net sales of the product;”
FILING10-K0001193125-26-110783cik 0001563880
“Further, in June 2023, we entered into a new sales agreement with Leerink Partners, LLC (formerly SVB Securities LLC), which we refer to as the ATM Sales Agreement, under which we may issue and sell shares of common stock, from time to time by any method that is deemed an "at-the-market" offering as defined in Rule 415(a)(4) under the Securities Act.”
FILING10-K0001193125-26-110783cik 0001563880
“We rely, and plan to continue to rely, on a single supplier, Par Health, which was spun off as an independent company after the merger between Mallinckrodt plc and Endo, Inc., for nalbuphine hydrochloride drug substance.”
FILING10-K0001193125-26-110783cik 0001563880
“Under the agreement, we have granted Keenova a non-exclusive, royalty-free (except for pass-through payments to third parties), sublicensable license under our relevant patent rights, to use any improvement we make to Endo's controlled release technology, for any product other than the products under which we are licensed by Endo.”
FILING10-K0001193125-26-110783cik 0001563880
“In accordance with the terms of the ATM Sales Agreement, the sales agreement we had entered into with SVB Securities LLC in 2020 terminated upon effectiveness of the 2023 Shelf Registration Statement, at which point we were no longer able to issue and sell shares of our common stock under such prior sales agreement.”
FILING10-K0001193125-26-110783cik 0001563880
Watchlist prices, news filtered to it, and its next report on your desk.
TRVI (Trevi Therapeutics, Inc.) has 4 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.